Luminopia
Cambridge, MA · United States
Specialization: VR-based digital therapeutic for amblyopia
Key Differentiator
Treats children with amblyopia using TV shows that are modified in real time in a VR headset.
Core Services
Luminopia VR treatment for amblyopia; Adherence portal for eye care providers; Licensing partnerships
Capabilities
Market Intelligence
FDA granted De Novo authorization in October 2021 and cleared an age expansion to 8 to 12 years in April 2025. Licensed the treatment to ROHTO Pharmaceutical for Japan.
Website
www.luminopia.comSimilar Companies
Think Research
Toronto, ON · Clinical Decision Support
TSX: THNK; Canadian digital health company serving 400+ hospitals/healthcare organizations; clinical decision support for drug safety and prescribing
Winterlight Labs
Toronto, ON · Speech-based digital biomarkers for clinical trials
Analyzes short speech samples to measure cognitive and mood changes in clinical trials.
Click Therapeutics
New York, NY · Prescription digital therapeutics
Co-develops FDA-cleared software treatments with pharma partners, such as Rejoyn with Otsuka.
Koneksa Health
New York, NY · Digital biomarkers and remote monitoring for trials
Builds digital biomarkers from remote data, such as its Parkinson's study that Merck and Regeneron joined through a data syndication program.
Need help finding the right outsourcing partner?
Try AI NavigatorCompany information is sourced from publicly available data and may not be current. PharmoniQ does not endorse any company listed. Contact companies directly for the most up-to-date information.